Cone photoreceptor cell death in inherited retinal diseases, such as Retinitis Pigmentosa (RP), leads to the loss of high acuity and color vision and ultimately to blindness. In RP, a vast number of mutations perturb the structure and function of rod photoreceptors while cones remain initially unaffected. Cone death follows rod death secondarily due to increased oxidative stress, inflammation, and loss of structural and nutritional support provided by rods. Here, we show that secondary cone cell death in animal models for RP was associated with an increased activity of histone deacetylates (HDACs). A single intravitreal injection of an HDAC inhibitor at a late stage of the disease, when majority of rods have already degenerated, was sufficient to delay cone death and support long-term cone survival. Moreover, the surviving cones remained light sensitive and initiated light-driven ganglion cell responses. RNA-seq analysis of protected cones demonstrated that HDAC inhibition led to multi-level protection via regulation of different pro-survival pathways, including MAPK, PI3K-Akt, and autophagy. This study suggests a unique possibility for a targeted pharmacological protection of both primary degenerating rods and secondary dying cones by HDAC inhibition and creates hope to maintain vision in RP patients independent of the disease stage.
Introduction
Blindness is a devastating condition, particularly so if it begins in early adulthood as it happens in certain hereditary diseases of the retina characterized by photoreceptor degeneration, such as in Retinitis Pigmentosa (RP). In RP, the leading cause of inherited blindness, mutations in more than 90 genes affect survival and function of rod photoreceptors or retinal pigment epithelium cells (RPE) (1, 2) (http://www.sph.uth.tmc.edu/Retnet/home.htm). One of the particularities of the disease is that despite mutation-unaffected, cone photoreceptors die secondarily once most rods are lost (3, 4) . In humans, loss of rods initially has only minor consequences for vision and the majority of patients are unaware of their condition until they start experiencing a prominent reduction in the central visual field, acuity or color discrimination, due to the loss of cones. Hence, in a clinical setting, it is highly pertinent to develop therapies for the treatment of advanced stages of RP, when majority rods have already degenerated and cone degeneration has set in (5, 6) .
Despite the importance of cones for human vision, studies on therapeutic options to prevent their loss at advanced stages of RP are disproportionally low (3, (7) (8) (9) (10) (11) . The reason for this could lie in intercellular relationship between rod and cone photoreceptors in human and mouse retina, where cones account for less than 5% of all photoreceptors (12) . Moreover, current knowledge suggests that the massive loss of rods in the late RP creates a "point of no return" after which cone cell death is unstoppable (6, 13) . When all rods have degenerated, cones are suffering from the loss of structural and nutritional support from rods (3, 14, 15) , exposure to oxidative stress (16) and inflammation (7, 11) . Although, alleviating each of these processes individually has the potential to preserve cones to some extent (3, 7, 9, 10, 14) , an ideal therapeutic option should provide multi-level protection of cones in the rod depleted retina. One way to achieve this could be by an epigenetically driven simultaneous regulation of a number of genes that are involved in diverse pro-survival responses.
Histone deacetylases (HDACs) are regulators of the chromatin structure and changes in their activity affect transcription of a number of genes (17, 18) . Tightly packed chromatin, following the HDAC-governed removal of acetyl groups from histones, is generally associated with transcriptional silencing, albeit this largely depends on the type and "health" status of cells (19) (20) (21) . Aberrant HDAC activity is causatively linked to various diseases ranging from cancer, through muscular dystrophies, to neurodegenerative diseases (22, 23) . We and others have previously shown that regulation of epigenetic patterns, via HDAC inhibition can protect primary degenerating photoreceptors in inherited retinal dystrophies caused by mutations in different genes (24) (25) (26) (27) (28) . Consequently, more than 90 clinical trials involving HDAC regulators stress HDAC inhibition as promising therapeutic approach for various diseases including retinal dystrophies (21, 29) .
Here, we investigated the involvement of HDACs in secondary cone degeneration in mouse models of RP. We found an increased HDAC activity present in both mutation-affected rods and in secondary dying cones. To assess the therapeutic potential of HDAC inhibition for the prevention of cone degeneration in RP, an HDAC inhibitor, Trichostatin A (TSA) was applied at an advanced stage of retinal degeneration, where essentially only a limited number of structurally collapsed cones were left. A single intravitreal injection afforded a long-term preservation of cone photoreceptors. Prolonged cone survival was accompanied by an increase in functional responses. Transcriptional changes associated with cone survival comprised regulation of distinct pro-survival mechanisms, including autophagy, MAPK and PI3K/Akt regulation. Therapies based on HDAC inhibition thus can offer a unique possibility to attenuate loss of photoreceptors independent of the stage of degeneration.
Results
Secondary cone degeneration in RP is associated with an increased HDAC activity. To assess the involvement of HDACs in the secondary cone degeneration, we used an HDAC in situ activity assay (26) at advanced stages of photoreceptor degeneration in two mouse models for RP, the rd1 and rd10 mice. Different mutations in the rod specific phosphodiesterase 6b (Pde6b) gene lead to fast rod photoreceptor degeneration, with the onset at post-natal day (PN) 9 in rd1 and PN14 in rd10 mice (4, 25, 30) . In both animal models cone degeneration begins once most rods have degenerated, around PN20 in the rd1 and PN40 in the rd10 mouse (3, 7) . At PN30, the outer nuclear layer (ONL) in rd1 mice is reduced to only one row of photoreceptors, almost exclusively cones ( Figure 1A ). To localize HDAC activity within the ONL, we combined the in situ HDAC activity assay with cone-and rod-specific immunostaining. In line with our previous results HDAC activity was detected in degenerating rods ( Figure 1A ) (25, 26) . Interestingly, HDAC activity also colocalized with the secondary degenerating cones ( Figure 1B) . The presence of HDAC positive cells within the ONL was detected through the entire period of cone cell death in rd1 mice ( Figure 1B ), while in no positive signal for HDAC activity was detected in nuclei of wildtype mice at PN14 (24) and PN30 (data not shown). These findings suggested that the cell death of both mutation-affected rods and secondary dying cones, involves HDAC overactivation. Along the same line, late stages of rd10 photoreceptor loss also included an increased HDAC activity ( Figure 1C , D). The time line of photoreceptor cell death in the rd10 mouse showed an early peak corresponding to the massive rod loss up to PN26 (30) ( Figure 1D ).
Following, a continuous photoreceptor cell death was detected, likely reflecting the simultaneous rod and cone loss. Similarly to the rd1 mouse, an increase in HDAC activity paralleled photoreceptor degeneration. The in situ assay in retinas from two months old rd10 mice revealed HDAC activity within a cone arrestin-labeled cone ( Figure 1C ), linking secondary cone degeneration to aberrant HDAC activity also in rd10 mice.
HDAC inhibition prolongs cone survival in rd1 mice. To determine if HDAC inhibition has a potential to prevent secondary cone degeneration, we injected a well-established class I and II HDAC inhibitor, TSA in the rd1 TN-XL mouse. rd1 TN-XL transgenic mice are homozygous for the mutant Pde6b allele and express the fluorescent TN-XL biosensor exclusively in cones, enabling their immediate visualization (31) . We have previously shown that a single intravitreal TSA injection prevents mutation-induced cone loss in the cpfl1 mouse up to 10 days post-injection (24) . Additionally, HDAC inhibition delays also primary rod degeneration in both rd1 and rd10 retinal explants (25, 26) . To minimize the indirect positive effects of increased rod survival afforded by HDAC inhibition on the rd1 cone survival, we selected a late time-point for the start of the treatment, PN19. Already from PN19, the rd1 TN-XL ONL is reduced only to one row of photoreceptors, almost exclusively cones (Figure 2A) . After a single intravitreal injection of TSA at PN19, the effects of HDAC inhibition on cone survival were assessed up to 3 months of age at different time points: PN26, PN30, PN37, PN45, PN60 and PN90. Whole-mount preparations of sham-injected eyes showed center to periphery gradient of cone loss at PN30 ( Figure 2B ). In contrast, an increased cone-specific fluorescent signal was detected in treated contralateral eyes ( Figure 2C ). At PN60 loss of cones had proceeded in control eyes, with cones remaining only at the far periphery ( Figure 2D ). TSA-treated eyes showed higher immunofluorescent signal, suggesting enhanced cone preservation even 41 days following the treatment ( Figure   2E ). An increase in cone survival was even more evident on retinal cross-sections ( Figure 2B '-E'', Supplementary Figure 1) , where individual cone cell bodies and remaining cone segments could be clearly identified. A higher number of cones in TSA-treated animals was also evident on retinal light micrographs ( Figure 2F -I'). While untreated retinas showed reduced density of nuclei, many of which were pyknotic, the treated retina displayed healthier cone morphology with classical heterochromatin distribution (32) ( Figure 1F -I'). The number of cones in the treated retina after one week remained at the same level as at the start of the treatment (12.03 ± 1.45 SEM cones/100 µm of ONL length at PN19 in untreated retinas vs. 12.39 ± 1.43 cones in the treated retina at PN26) ( Figure 2J ). In the control retinas cone degeneration continued with ~ 15% less cones than at the start of the treatment (10.12 ± 0.7 SEM in control retinas at PN26).
A plot of cone numbers up to PN90 showed that cone loss in control and treated retinas followed an exponential decay function with a clear separation of the two curves ( Figure 2J ).
Additionally, fitted trend lines showed broader separation of the two curves from PN60 and predicted an X-axis intersection of the treated curve with 16 days delay to the control (PN79 for treated vs. PN95 control retinas, Figure 2J ). These extrapolations suggest that the TSA treatment not only delays but might slow down secondary cone degeneration as well.
To analyze the effects of continuous TSA treatment on cone survival, we treated rd1 TN-XL retinal explants from PN19 until PN26 ex vivo. Organotypic retinal cultures, consisting of retina and RPE layer, enable maintaining mature neurons in situ, as well as complex neuronal connections, while providing the possibility for constant exposure to a drug via a culture medium ( Figure 3A ). Similarly to rd1 TN-XL cone degeneration in vivo, the center to periphery gradient of cone loss was more prominent in the control explant cultures ( Figure 3B ).
Quantification of cone numbers in retinal cross-sections showed ~30% increase in the cone survival in TSA-treated retinal explants ( Figure 3B ).
Next, we asked if the HDAC inhibition has a potential to protect secondary dying cones even at a later stage of degeneration. For this, we started the treatment at PN21 and assessed the rd1 TN-XL cone survival after one week in culture ( Figure 3C ). Also in this case, the TSA treatment significantly improved cone survival, with 52% more cones in the treated explants (6.03 ± 0.69 cones/100 µm of length in the TSA-treated explants vs. 3.16 ± 0.62 SEM in the controls, n=5, p=0.0147). We also tested the neuroprotective properties of Panobinostat, a clinically approved pan-HDAC inhibitor within the same group of inhibitors as TSA (33, 34) .
Similarly to TSA, Panobinostat treatment starting at PN19, increased rd1 TN-XL cone survival ex vivo up to 30% after 7 days (Supplementary Figure S2 ). Figure 4D ).
HDAC inhibition induces global changes in gene-transcription patterns in the surviving
cones. To gain an insight into molecular signatures governing the TSA-induced cone survival, we performed whole transcriptome analysis of flow-sorted rd1 TN-XL cones of retinal explants after seven days in culture (PN19-26). TN-XL+ cells represented 95% of FASC-sorted cells, suggesting a highly purified cone population (Supplementary Figure S3 ). RNA-seq analysis of differentially expressed genes (DEG) in TSA-treated vs. untreated cones revealed 1845 genes with significantly different expression (enrichment of 1163 and reduction in 682 genes), as indicated in the volcano plot ( Figure 5A ). The complete list of differentially expressed genes is provided in Supplementary table 2. Regulation of signaling pathways can be influenced by coordinated subtle changes in proteins abundance and modifications, rather than the level of expression of individual genes (37, 38) . As RNAseq data provide information about gene expression levels that may not necessarily influence protein abundance (39), we focused our analysis on changes in pathways modulation. Therefore, for the pathway analysis we used protein-coding genes with significant differential expression following the TSA treatment (p≤ 0. (20/36, mmu04010) in the TSA-treated cones ( Figure 5B ). Among highly abundant transcripts were the brain-derived neurotrophic factor (Bdnf) and the insulin-like growth factor 1 (Igf1), growth factors regulating MAPK and PI3K-Akt pathways. Significantly increased Bdnf expression in the TSA-treated cones sorted from independent samples was confirmed by quantitative PCR (qRT-PCR) ( Figure 5C ). Moreover, the pathway analysis showed significant upregulation of most of the genes (9/14) related to autophagy (mmu04140), an additional pro-survival mechanism in neurodegenerative diseases ( Figure 5B ) (42, 43) . Upregulation of the autophagy-related-5 gene (Atg5) in surviving cones was confirmed by qRT-PCR ( Figure 5C ). While, RNAseq data suggested downregulation of Mtor and Mlst8, regulators of both MAPK and autophagy pathways, qRT-PCR on independent samples showed significant upregulation in the treated cones. To evaluate if increased Atg5 transcription was resulting in increased autophagy, we assessed formation of autophagolysosomes in surviving cones. To this end, we quantified the colocalized puncta between an autophagosome marker, the microtubule-associated proteins 1A/1B light chain 3B (LC3B) and lysosome-associated membrane protein 1 (LAMP1) in control and treated rd1 TN-XL cones. LC3-LAMP1 staining of retinal cross-section from PN19-26 in vivo TSA-treated mice showed overall increase in both LC3-and LAMP1-positive vesicles, as well in colocalizing puncta within the cones in comparison to sham-treated retinas ( Figure 6) . Similarly, increased LC3-LAMP1 colocalization in cones was also detected in ex vivo treated rd1 TN-XL explants (Supplementary Figure S4 ).
Finally, to identify similar molecular signatures to the expression pattern obtained in this study, we submitted our data to the Library of Integrated Network-Based Cellular Signatures project, (LINCS) (Supplementary Figure S5) (44) . The analysis matched our data to gene expression profiles of TSA and Vorinostat treatments on human cell lines deposited in the LINCS platform. Of note, Vorinostat is a clinically approved pan-HDAC inhibitor from the same class as TSA. This suggests a possibility for the repurposing of "off the shelf" HDAC-inhibiting drugs for the treatment of RP.
Discussion
Cone photoreceptors are indispensable for human vision in daylight and their loss in inherited or acquired retinal diseases have devastating effects on daily tasks and life quality (27, 45, 46) .
In RP, mutations in any of 90 identified genes will not only lead to loss of rods, but will ultimately result in cell death of cones despite them being not directly affected by mutations (47, 48) . Dependence of cones on rods' survival is considered to be crucial, as loss of 95% of all photoreceptors will expose the remaining cones to oxidative stress, inflammation, nutritional deficit, as well as loss of the structural and trophic support normally provided by rods (3, 7, (14) (15) (16) . However, despite such adverse environmental conditions and loss of their functionality, cones can persist for a long time in RP patients. Dormant cones retain cell bodies long after the loss of outer and inner segments, as well as a potential for structural and functional revival under certain conditions, such as optogenetic reactivation or upon transplantation of rods (49, 50) .
Here, we show that cones also have an innate ability for survival in the total absence of rods, which can be induced by HDAC-driven transcriptional changes. At the same time HDAC inhibition may affect other cells in the retina, which could support cone survival in the absence of rods (51, 52) . A single intravitreal injection of HDAC inhibitor fully protected cones for one
week and significantly slowed down cone loss up to 90 days even when all rods had already degenerated. Interestingly, the rd1 TN-XL cone loss followed exponential kinetics as already suggested for other forms of neurodegeneration (53) . The observed exponential cone loss in the rd1 TN-XL retina excludes the possibility of cumulative damage caused by the loss of rods, and suggests that secondary dying cones can be rescued at any time, although with the disease progression fewer cells will be amenable for rescue. Therefore, a treatment even at late stages of disease is likely to be beneficial (53) . Indeed, our data on HDAC-induced cone protection at different stages of rd1 TN-XL cone loss (PN19 and PN21) confirm this and is furthermore in line with other observations indicating that the window-of-opportunity for the treatment of retinal dystrophies is much broader than it is currently considered (Samardzija et al., in press, (6)).
Preserving retinal function in the absence of rods is the ultimate goal of neuroprotective therapies for late stage RP. Indeed, recent studies demonstrated some improvements in visual function, following therapies specifically targeting cones in mouse models of RP with slower degeneration and at stages where most of rods are still present (7, 9) . However, the low number and the impaired morphology of the remaining cones at the stages where rods have already fully degenerated is a major obstacle in assessing visual improvements by standard functional tests like ERG (54) . We did not detect changes in ERG-wave amplitudes in rd1 TN-XL In advanced RP cones are exposed to high oxidative stress and inflammation (7, 16, 59) .
Oxidation induced injury at the cellular level elicits a broad range of responses, from proliferation to cell death, that largely depend on the balance between various cell signaling pathways activated as a response to oxidative stress (60) . Our data point to changes in two major signaling pathways involved in regulating cellular response to oxidative stress, the mitogen-activated protein kinases (MAPK) and phosphoinositide 3-kinase activated protein (62) . In addition, a positive involvement of p38 MAPK was later causally connected to LIF-dependent neuroprotection during photoreceptor degeneration (63) . On the other hand, the importance of the PI3K-Akt pathway in photoreceptor survival is well-established, with PI3K-Akt members acting downstream of various neuroprotective agents (64, 65) . In addition, the PI3K-Akt pathway connects extracellular signals, such as insulin, with the mTOR pathway shown to play an important role in secondary dying cones (3, 9) . RNA-seq data obtained in this study indicate regulation of more than 40 genes within the PI3K-Akt pathway, further confirming the PI3K-Akt pathway as one of the major regulators of cone survival in RP. Similarly, MAPK and PI3K-Akt regulation is also associated with inflammation in various neurodegenerative conditions, including retinal diseases (66, 67) . Interestingly, our data suggest that an increase in transcription of neurotrophic factors, including Igf1 and Bdnf, may contribute to cone survival.
Although BDNF-induced neuroprotective effects on light-or mutation-induced photoreceptor degeneration was recognized as early as 1992 by LaVail and colleagues (68, 69) our study indicate a direct upregulation of Bdnf transcription in the cones protected from secondary degeneration.
Besides increased oxidative stress and inflammation, cone starvation has recently been recognized as one of the main contributors to secondary cone death in RP (3, 9, 14) . Autophagy is the main cellular mechanism for self-nourishment and recycling of metabolites to supplement macromolecules and energy under severe starvation (42, 43) . The beneficial role of autophagy is demonstrated for the clearance of misfolded proteins in mutation-affected photoreceptors or in dysfunctional RPE in age-related macular degeneration (AMD) (70) (71) (72) (73) .
Yet, in secondary cone degeneration it remained unclear whether increased autophagy is beneficial or not (3, 74, 75) . The observed upregulation of Atg5 transcription and an increased number of autophagolysosomes in TSA-treated cones are in line with the previously reported effects of HDAC inhibition on autophagy induction (76) and highlight autophagy as a protective mechanism in secondary cone degeneration. Interestingly, while RNA-seq analysis of transcriptional regulation following the TSA treatment suggested differential regulation of both autophagy and mTOR pathways, via downregulation of Mtor and Mlst8 among other genes, qRT-PCR validation showed significant upregulation of both transcripts. Whether the observed differences in the TSA-induced transcriptional regulation of Mtor and Mlst8 will induce an activation of the mTOR pathway, associated with an increased cone survival in RP (3, 9) , requires further studies. Intravitreal injections. Single intravitreal injections were performed at PN19 in rd1 TN-XL mice that were anesthetized subcutaneously with a mixture of ketamine (85 mg/kg) and xylazine (4 mg/kg). One eye was injected with 0.5 µl of a 100 nM TSA (catalog T8552, Sigma-Aldrich) in 0.0001% DMSO, while the contralateral eye was sham-injected with 0.0001% DMSO and served as a control. Assuming the intraocular volume of mouse eye to be 5µl (82) , this procedure resulted in a final intraocular concentration of 10 nM TSA.
Retinal explant cultures. Organotypic retinal cultures from rd1 TN-XL animals including the
retinal pigment epithelium (RPE) were prepared under sterile conditions as previously described (24, 25) . Briefly, PN19 or PN21 animals were sacrificed, the eyes enucleated and pretreated with 0.12% proteinase K (ICN Biomedicals Inc.) for 15 minutes at 37°C in HBSS (Invitrogen Inc.). Proteinase K activity was blocked by addition of 10% fetal bovine serum, followed by rinsing in HBSS. In the following, the cornea, lens, sclera and choroid were removed, while the RPE remained attached to the retina. The explant was cut into a clover-leaf shape and transferred to a culture membrane insert (Corning Life Sciences,) with the RPE facing the membrane. The membrane inserts were placed into six well culture plates with Neurobasal-A medium (catalog 10888022) supplemented with 2% B27 (catalog 0080085-SA), 1% N2 (catalog 17502048) and L-glutamine (0.8 mM, catalog 25030032) (all from Invitrogen Inc.), and incubated at 37°C in a humidified 5% CO2 incubator. The culture medium was changed every 2 days during the 7 days culturing period. Retinal explants were treated with 10 nM TSA or 1 µM Panobinostat (catalog S1030, Selleckchem) diluted in Neurobasal-A culture medium. For controls, the same amount of DMSO was diluted in culture medium. Culturing was stopped after 7 days by 2 h fixation in 4% PFA, cryoprotected with graded sucrose solutions containing 10, 20, and 30% sucrose and then embedded in tissue freezing medium (Leica Microsystems Nussloch GmbH).
Histology. For retinal cross-sectioning, the eyes were marked nasally and eye cups (after cornea, iris, lens and vitreous removal) were fixed in 4% paraformaldehyde for 2 hours at room temperature. Following graded sucrose cryoprotection eyes were embedded in optimal cutting temperature compound (Tissue-Tek), cut into 12 μm sections and mounted with Vectashield medium containing 4',6-diamidino-2-phenylindole (DAPI, Vector). For retinal flat mounts, retinas without RPE were fixed for 30 minutes, cut into a clover leaf shape and mounted with Vectashield with the photoreceptors facing up. To analyze retinal morphology, eyes were fixed in 2.5% glutaraldehyde, cut at the level of the optic nerve, followed by 1% osmium tetroxide treatment post fixation and ethanol dehydration, according to a previously described protocol (32) . After embedding in Epon 812, 0.5 μm thick sections were counterstained with toluidine HDAC in situ activity assay. HDAC activity assays were performed on 12 µm thick cryosections of 4% PFA-fixed eyes following immunostaining against cone arrestin/rhodopsin as previously described (4) . Briefly, retina sections were exposed to 200 μM Fluor de Lys-SIRT2 deacetylase substrate (Biomol) with 500 μM NAD + (Biomol) in assay buffer (50 mM Tris/HCl, 137 mM NaCl; 2.7 mM KCl; 1 mM MgCl 2 ; pH 8.0) for 3 hours at room temperature. Following methanol fixation at -20°C for 20 min, a developer solution (1x Biomol; KI105) containing 2 μM TSA and 2 mM nicotinamide in assay buffer was applied to generate the signal. Due to the presence of a background staining in negative controls, only cells with a prominent nuclear staining were considered as HDAC positive (24) . Following incubation with trypsin inhibitor (Sigma-Aldrich) cell suspension was washed with HBSS and passed through a 40-µm filter before fluorescence activated sorting (FACS). One biological replicate included at least 2 retinal explants prepared from different animals. Three independent biological replicates from control and TSA-treated retinal explants were used for cone photoreceptor FACS using an ARIAIII cell sorter (BD Biosciences). The sort was performed with a 100 µm nozzle tip, at a sheath pressure of 20.0 psi, and with purity precision. TNXL positive cone photoreceptors were gated as follows: singlets forward scatter (FSC-A vs FSC-H) /
singlets side scatter (SSC-A vs SSC-H) / viable cells (FSC-A vs SSC-A) / TNXL+ cells (FSC-A vs TNXL-
A) (gating Supplementary Figure 3A (Illumina) with a depth of >20 million reads. Library preparation and sequencing procedures were performed by the same individual and a design aimed to minimize technical batch effects.
Data quality of raw RNA-seq reads in FASTQ files was assessed using ReadQC (ngs-bits version 2018_04) to identify potential sequencing cycles with low average quality and base distribution bias. Reads were preprocessed with Skewer (version 0.2.2) and aligned using STAR (version 2.5.4a), allowing spliced read alignment to the mouse reference genome (Ensembl Mus musculus GRCm38). Alignment quality was analyzed using MappingQC (ngs-bits version 2018_04) and visually inspected with Broad Integrative Genome Viewer (version 2.4.0). Based on the genome annotation ITAG (Ensembl 75), normalized read counts for all genes were obtained using subread (version 1.6.0) and edgeR (version 3.28.0). Raw counts data were processed using iDEP, an integrated web application for RNA-seq data analysis (86) . To provide access to RNAseq data, we generated a BioJupies notebook (87) Figure 2J was obtained by averaging all the analyzed positions from all the animals per stage.
Ex vivo survival was quantified on 5-12 different positions, from 3-5 retinal cross-sections obtained from different positions within a retinal explant. Unpaired, two-tailed t tests were used to compare controls with treatments.
Statistical differences for LC3-LAMP1 puncta quantification and qRT-PCR were calculated using
Mann-Whitney nonparametric test.
RNAseq raw data were processed and normalized using subread (version 1. 
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